Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2023
About
Suggestions
Contact Us
telisotuzumab vedotin
MeSH Supplementary Concept Data 2024
Details
Concepts
MeSH Supplementary
telisotuzumab vedotin
Unique ID
C000626235
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C000626235
Entry Term(s)
ABBV-399
ABT-399
ABT-700-VCMMAE
PR-1420682
Registry Number
976X9VXC3Z
Heading Mapped to
*Antibodies, Monoclonal
Frequency
6
Note
c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence
Source
Clin Cancer Res. 2017 Feb 15;23(4)992-1000
Date of Entry
2018/02/12
Revision Date
2019/11/01
Expand All
Collapse All
telisotuzumab vedotin
Preferred
Concept UI
M000654539
Registry Number
976X9VXC3Z
Terms
telisotuzumab vedotin
Preferred Term
Term UI
T000965999
Date
08/21/2019
LexicalTag
NON
ThesaurusID
NLM (2020)
PR-1420682
Narrower
Concept UI
M000654540
Terms
PR-1420682
Preferred Term
Term UI
T000966001
Date
08/21/2019
LexicalTag
LAB
ThesaurusID
NLM (2020)
ABT-700-VCMMAE
Narrower
Concept UI
M000654541
Terms
ABT-700-VCMMAE
Preferred Term
Term UI
T000966002
Date
08/21/2019
LexicalTag
LAB
ThesaurusID
NLM (2020)
ABBV-399
Narrower
Concept UI
M000640969
Terms
ABBV-399
Preferred Term
Term UI
T000940316
Date
02/12/2018
LexicalTag
LAB
ThesaurusID
NLM (2017)
ABT-399
Term UI
T000966000
Date
08/21/2019
LexicalTag
LAB
ThesaurusID
NLM (2020)
page delivered in 0.006s